FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238911441> ?p ?o ?g. }

• W4238911441 abstract "Background Tumour necrosis factor (TNF)‐alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with certolizumab pegol that was first published in 2011. Objectives To assess the clinical benefits and harms of certolizumab pegol (CDP870) in patients with RA who have not responded well to conventional disease‐modifying anti‐rheumatic drugs (DMARDs). Search methods We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2014, Issue 5), MEDLINE, EMBASE, Scopus, TOXLINE, Web of Knowledge; websites of the US Food and Drug Administration (FDA) and European Medicines Evaluation Agency (EMEA); reference lists of articles; and searched http/clinicaltrials.gov. The searches were updated from 2009 (date of last search for the original review) to 5 June 2014. Selection criteria Randomised controlled trials that compared certolizumab pegol with any other agent including placebo or methotrexate (MTX) in adult patients with active RA despite current or prior treatment with conventional disease‐modifying anti‐rheumatic drugs (DMARDs), such as MTX. Data collection and analysis Two authors independently assessed search results, trial quality and extracted data. Disagreements were resolved by discussion or referral to a third author. Main results Eleven trials were included in this update. Ten (4324 patients) were included in the pooled analysis for benefits, five more than previously, and 10 (3711 patients) in the pooled analysis for harms, four more trials (1930 patients) than previously. The duration of follow‐up varied from 12 to 52 weeks and the range of doses of certolizumab pegol varied from 50 to 400 mg given subcutaneously (sc). In phase III trials, the control was placebo plus MTX in five trials and placebo in four trials. The risk of bias of the included studies was assessed as low but there may have been a risk of attrition bias. Statistically significant improvements were observed at 24 weeks with the approved dose of 200 mg certolizumab pegol every other week, in 1) American College of Rheumatology (ACR) 50% improvement: 27% absolute improvement (95% CI 20% to 33%), NNT of 4 (95% CI 3 to 8), risk ratio (RR) 3.80 (95% CI 2.42 to 5.95); 2) the Health Assessment Questionnaire (HAQ): ‐12% absolute improvement (95% CI ‐9% to ‐14%), NNT of 6 (95% CI 5 to 8), mean difference (MD) ‐ 0.35 (95% CI ‐0.43 to ‐0.26) (scale 0 to 3); 3) Disease Activity Score (DAS) remission improvement: absolute improvement 11% (95% CI 8% to 15%), NNT of 9 (95% CI 4 to 20), RR 8.47 (95% CI 4.15‐17.28); and 4) radiological changes: erosion score (ES) absolute improvement ‐0.29% (95% CI ‐0.42% to ‐0.17%), NNT of 6 (95% CI 4 to 10), MD ‐0.67 (95% CI ‐0.96 to ‐0.38) (scale 0 to 230). Serious adverse events were statistically significantly more frequent for certolizumab pegol (200 mg every other week) with an absolute rate difference of 4% (95% CI 2% to 6%), NNTH of 32 (95% CI 17 to 88), Peto odds ratio (OR) 1.77 (95% CI 1.27 to 2.46). There was a statistically significant increase in all withdrawals in the placebo groups (for all doses and all follow‐ups) with an absolute rate difference of ‐34% (95% CI ‐18% to ‐50%), NNTH of 4 (95% CI 3 to 5), NNTH of 4 (95% CI 3 to 5), RR 0.42 (95% CI 0.36 to 0.50); and there was a statistically significant increase in all withdrawals due to adverse events in the certolizumab groups (for all doses and all follow‐up) with an absolute rate difference of 2% (95% CI 1% to 3%), NNTH of 55 (95% CI 27 to 238), Peto OR 1.66 (95% CI 1.15 to 2.37). The risk of bias was low and the quality of evidence was downgraded to moderate because of high rates of dropouts (> 20%) in most of the trials. We did not find any problems with inconsistency, indirectness, imprecision or publication bias. Authors' conclusions The results and conclusions did not change from the previous review. There is moderate‐level evidence from randomised controlled trials that certolizumab pegol alone or combined with methotrexate is beneficial in the treatment of RA. Adverse events were more frequent with active treatment. We found a potential risk of serious adverse events." @default.
• W4238911441 created "2022-05-12" @default.
• W4238911441 creator A5000077040 @default.
• W4238911441 creator A5023035949 @default.
• W4238911441 creator A5025085644 @default.
• W4238911441 creator A5028984464 @default.
• W4238911441 creator A5066037713 @default.
• W4238911441 creator A5087068978 @default.
• W4238911441 creator A5088634416 @default.
• W4238911441 date "2014-09-18" @default.
• W4238911441 modified "2023-10-18" @default.
• W4238911441 title "Certolizumab pegol (CDP870) for rheumatoid arthritis in adults" @default.
• W4238911441 cites W1513749108 @default.
• W4238911441 cites W1598602811 @default.
• W4238911441 cites W1701993624 @default.
• W4238911441 cites W1761300068 @default.
• W4238911441 cites W1881645841 @default.
• W4238911441 cites W1908778477 @default.
• W4238911441 cites W1968608249 @default.
• W4238911441 cites W1969559624 @default.
• W4238911441 cites W1973460930 @default.
• W4238911441 cites W1976992856 @default.
• W4238911441 cites W1978007661 @default.
• W4238911441 cites W1987494572 @default.
• W4238911441 cites W1988524499 @default.
• W4238911441 cites W1994970711 @default.
• W4238911441 cites W2005885148 @default.
• W4238911441 cites W2005911107 @default.
• W4238911441 cites W2006423433 @default.
• W4238911441 cites W2006566716 @default.
• W4238911441 cites W2006712764 @default.
• W4238911441 cites W2007314153 @default.
• W4238911441 cites W2011520765 @default.
• W4238911441 cites W2017766892 @default.
• W4238911441 cites W2019832147 @default.
• W4238911441 cites W2031494385 @default.
• W4238911441 cites W2031838098 @default.
• W4238911441 cites W2031988556 @default.
• W4238911441 cites W2032792840 @default.
• W4238911441 cites W2045575508 @default.
• W4238911441 cites W2046220194 @default.
• W4238911441 cites W2046657252 @default.
• W4238911441 cites W2046990636 @default.
• W4238911441 cites W2048033195 @default.
• W4238911441 cites W2049909893 @default.
• W4238911441 cites W2061900452 @default.
• W4238911441 cites W2065288134 @default.
• W4238911441 cites W2066261649 @default.
• W4238911441 cites W2067717482 @default.
• W4238911441 cites W2067917639 @default.
• W4238911441 cites W2069973593 @default.
• W4238911441 cites W2071636984 @default.
• W4238911441 cites W2071953739 @default.
• W4238911441 cites W2075619622 @default.
• W4238911441 cites W2076011146 @default.
• W4238911441 cites W2078110114 @default.
• W4238911441 cites W2079759594 @default.
• W4238911441 cites W2084433985 @default.
• W4238911441 cites W2085318733 @default.
• W4238911441 cites W2088306427 @default.
• W4238911441 cites W2089242190 @default.
• W4238911441 cites W2092404711 @default.
• W4238911441 cites W2099199787 @default.
• W4238911441 cites W2106171259 @default.
• W4238911441 cites W2106453726 @default.
• W4238911441 cites W2106799757 @default.
• W4238911441 cites W2106964599 @default.
• W4238911441 cites W2107883387 @default.
• W4238911441 cites W2108849668 @default.
• W4238911441 cites W2110586471 @default.
• W4238911441 cites W2115016130 @default.
• W4238911441 cites W2116996289 @default.
• W4238911441 cites W2125501404 @default.
• W4238911441 cites W2128775174 @default.
• W4238911441 cites W2131882149 @default.
• W4238911441 cites W2133866209 @default.
• W4238911441 cites W2133996321 @default.
• W4238911441 cites W2135453000 @default.
• W4238911441 cites W2137592803 @default.
• W4238911441 cites W2141706104 @default.
• W4238911441 cites W2143439165 @default.
• W4238911441 cites W2148311007 @default.
• W4238911441 cites W2148692760 @default.
• W4238911441 cites W2149569832 @default.
• W4238911441 cites W2152348310 @default.
• W4238911441 cites W2155109530 @default.
• W4238911441 cites W2162254515 @default.
• W4238911441 cites W2163817180 @default.
• W4238911441 cites W2167396572 @default.
• W4238911441 cites W2168370388 @default.
• W4238911441 cites W2170521505 @default.
• W4238911441 cites W2262242462 @default.
• W4238911441 cites W2318165541 @default.
• W4238911441 cites W2327557677 @default.
• W4238911441 cites W2764515646 @default.
• W4238911441 cites W2791241075 @default.
• W4238911441 cites W4210768724 @default.
• W4238911441 cites W4233594447 @default.
• W4238911441 cites W4239255546 @default.
• W4238911441 cites W4242550450 @default.

• next